Lazard Asset Management’s GeneDx Holdings WGS Stock Holding History

Lazard Asset Management’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.26M	Sell	32,852 -1,042	-3%	-$59.2K	﹤0.01%	930
2026 Q1	$2.18M	Buy	+33,894	New	+$3.09M	﹤0.01%	852
2025 Q1	–	Sell	-457	Closed	-$35K	–	2601
2024 Q4	$35K	Buy	+457	New	+$31.9K	﹤0.01%	2034

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Lazard Asset Management's WGS Position: Q2 2026 in Review

Lazard Asset Management reduced its GeneDx Holdings (WGS) stake by 3.1% in Q2 2026, selling an estimated $59.2K and leaving 32,852 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #930.

Lazard Asset Management first reported a position in WGS in Q4 2024 and has held it in 3 quarters since. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

Lazard Asset Management held 32,852 shares of GeneDx Holdings worth $2.26M as of Q2 2026.
Lazard Asset Management sold 1,042 GeneDx Holdings shares in Q2 2026, an estimated $59.2K.
GeneDx Holdings made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #930 holding.
Lazard Asset Management first reported a position in GeneDx Holdings in Q4 2024 and has held it in 3 quarters since.
223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.